Novocure
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United...
Latest News
3 days ago · businesswire.com
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic CancerBAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line tre.
6 days ago · fool.com
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.
8 days ago · businesswire.com
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung CancerBAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune.
15 days ago · zacks.com
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the StockExplore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
15 days ago · fool.com
NovoCure: 3 Key Takeaways for Long-Term InvestorsNovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.
18 days ago · seekingalpha.com
NovoCure Limited (NVCR) Q3 2026 Earnings Call TranscriptNovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackmann - Chief Financial Officer Uri Weinberg - Chief Innovation Officer & Chief Medical Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Tanmay Patwardhan - JPMorgan Chase & Co. Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions] Please note, this call may be recorded.
18 days ago · marketbeat.com
NovoCure Q3 Earnings Call HighlightsNovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.
19 days ago · zacks.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesNovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.
20 days ago · businesswire.com
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply AgreementBAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.
1 month ago · seekingalpha.com
Novocure: A Mispriced Cash-Generating Biotech With Upside PotentialNovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NVCR